Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
公司代碼GH
公司名稱Guardant Health Inc
上市日期Oct 04, 2018
CEOTalasaz (Amirali)
員工數量1999
證券類型Ordinary Share
年結日Oct 04
公司地址3100 Hanover Street
城市PALO ALTO
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編94304
電話18556988887
網址https://guardanthealth.com/
公司代碼GH
上市日期Oct 04, 2018
CEOTalasaz (Amirali)